Amanda G.’s Post

𝗦𝗲𝗻𝗶𝗼𝗿 𝗧𝗮𝗹𝗲𝗻𝘁 𝗦𝗵𝗶𝗳𝘁 𝗤𝟮 𝟮𝟬𝟮𝟰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 In Q2 2024, there have been notable senior-level changes across the Real World Evidence, Digital Health, Consulting, and CDMO sectors. These shifts reflect the industry's ongoing evolution and the increasing demand for leaders with expertise in business transformation, strategic change, and entrepreneurial drive. In the Real World Evidence sector, new senior leaders have been appointed to spearhead efforts in leveraging real-world data for enhanced clinical and commercial insights. These changes aim to strengthen capabilities in generating robust evidence to support regulatory submissions and market access strategies in a highly competitive field, marked by fierce competition from both large corporations and smaller enterprises. 𝗨𝗦𝗔 Kyle Armbrester - CEO at Datavant Brett Kleger - CEO at Inspire Rachael Thomas Higgins - CCO at PicnicHealth Jade Cusick - CCO at Ontada Ben Stormer - CCO at Annexus Health Ryan Sloan - CGO at Galileo Jennifer M. - CGO at Lightship Lindsay Daniel - CHRO at YPrime Joshua Max Davis - SVP Commercial Operations at Ada Health Amy Eaves - BU Head Healthcare & Life Sciences at Synoptek 𝗘𝘂𝗿𝗼𝗽𝗲 Marc Funk - CEO at MARBIO Abdelaziz Toumi, PhD, MBA - CEO at Lupin Jonathan Burr - CCO at Cytel Martin Keil - VP & GM at Revvity Roberto Ascione - President at EVERSANA Pamela V. - VP HEOR, Value & Evidence at EVERSANA Jean-Christophe Massot - VP Information & Communications ProductLife Group Frédéric GAUSSENS - VP Europe & APAC PharmaLex We are excited to see how Q3 unfolds with any future senior talent shifts. If you are seeking senior-level opportunities or looking to attract senior talent, please contact our executive search team at Luminary Group. Stay tuned for the next series! #realworldevidence #rwe #rwd #regulatoryaffairs #cdmo #pharmaceutical #biotechnology

🌟📢 Hey there, social media enthusiasts! 🌟📢 🔥🔍 Are you ready for some mind-blowing insights on Johnson & Johnson? 🔥🔍 🤔💼 Is Johnson & Johnson the perfect investment opportunity or just another pharmaceutical giant? Find out in this article! 💼🤔 💰💊 RBC Capital Markets believes that Johnson & Johnson is a great investment opportunity, thanks to its recent spinoff of its consumer business. This separation has "unlocked potential" for the company, making it the only global healthcare company with Pharma and MedTech under one portfolio. 💊💰 🚀📈 With a clear focus on innovation and enhanced productivity, Johnson & Johnson is perfectly positioned for higher revenue and margins. Its pharmaceutical franchise and medtech division are expected to experience strong growth, promising lucrative returns! 📈🚀 💡🔬 The company's pipeline includes five therapies with a revenue potential of over $5 billion and twelve therapies with a potential revenue of over $1 billion. Plus, its medtech division is gaining sales in growing markets and focusing on innovative products, such as surgical and orthopedic robotics. 🔬💡 💼💰 Despite trading below historical multiples, Johnson & Johnson is an attractive investment opportunity with potential upside from further M&A activity. 💰💼 📈💼 Don't miss out on this investment gem! RBC Capital Markets believes Johnson & Johnson is a BUY, with a target price of $178, suggesting a potential increase of about 14.5% from Wednesday's close. 📈💼 🔗🔍 For more details, check out the full article here: 🔍🔗 🤩😲 Get ready to dive into the exciting world of Johnson & Johnson! 😲🤩 🔥🚀 Invest wisely and stay ahead of the game! 🔥🚀 #InvestmentOpportunity #PharmaceuticalGiant #JohnsonAndJohnson #FinancialInsights #StayAhead #InvestWisely 📈💼💰 💬💡 What are your thoughts on Johnson & Johnson? Share your opinions in the comments below! 💡💬 👉🔁 Don't forget to like, share, and spread the word about this investment gem! Let's help others make informed decisions as well! 👈🔁 #ShareTheKnowledge #InvestmentTips #SpreadTheWord #SmartInvesting 📢💡 Keep rocking the social media game, folks! 🎉💪 #SocialMediaGameOnPoint #SocialMediaExpert #StayInformed 💻📱💼 ✨🌟 #StayCurious, #StaySkeptical, and above all, #StayEntertained! ✨🌟 https://lnkd.in/dE6vKtiU

⏰ The #DTxWest 2024 Summit full agenda and speaker faculty has officially launched and we can't wait for you to dive in and check it out! 🙌 We've taken the DTx Conference to the next level by introducing four dedicated tracks: Commercial, Evidence-Based, The Role of Pharma, and Adopting DTx. Throughout the program, you can look forward to a captivating blend of workshops, networking sessions, thought-provoking panel discussions, and engaging presentations that promise an enriching experience. If you're involved in or considering a role in the digital healthcare sector 🤔, you've come to the right place. Join a diverse group of industry leaders, including those from #Pharma, #DTx, #HealthcareProviders, #Clinicians, #Payers, #Academia, #Investors, #Government Officials, #Policymakers and more. Together, we can't wait to come together and revitalize DTx within the healthcare market. ✔ Check out the full agenda today and register your place here: www.dtxwest.com Welldoc, National Institute of Mental Health (NIMH), Highmark Inc., UnitedHealth Group, BRAVEN, Bayer, UPMC, Children's Integrated Center for Success, DigiTx Partners, Samsung Medical Center, Amen Clinics, Inc., AMCP, Stanford University School of Medicine, DG Daiwa Ventures - GP of DG Lab Fund, Boehringer Ingelheim, Swing Therapeutics, Inc., MedRhythms, Inc., Kaiser Permanente, Digital Medicine Society (DiMe), Akili, Mymee, Genentech, Click Therapeutics, Inc., DTxCC (Digital Therapeutics Commercialization Consultants, LLC), Digital Therapeutics Alliance, Liquid Amber, Woebot Health, Point32Health, OMRON Group, Allegheny Health Network, Digital Health Today, Walgreens, Alex Therapeutics, Amwell, Boston University #digitalhealth #digitaltherapeutics #dtx #healthcare #conference

When we founded Lead Candidate we were clear about our mission to have a positive impact on the businesses and people that make up #pharma services, for the benefit of the sector as a whole and the patients it ultimately serves. Sharing knowledge and insights, is just one route we have embraced to make an impact. So when we were approached by Alex Stoner and GBR to contribute to the 2024 US Life Sciences report, we we're all too happy to get involved. If you haven't seen the report ⬇️ then I would recommend reading it. From the financial and regulatory environment to new technologies, the report offers a comprehensive assessment into key themes impacting the sector as well as invaluable contributions and interviews from industry leaders. My small input obviously focuses on the talent agenda, the evolving landscape of human resources and how this is a strategic imperative for the future development of our sector. #talent #outsourcing #cdmo #cro

To fully embrace and reap the benefits of next-gen technologies, your organization must be primed and ready. On March 20th at #AGBreakthrough, Julie Thomas, Pharm.D, RPh, Vice President of Global Medical Safety Operations, will share Johnson & Johnson's journey towards #PV transformation and how they're approaching organizational readiness: https://lnkd.in/e48tTh_8

As a Chief of Staff in a tech-savvy biopharma company, I'm closely following the presidential debate today. It's always intriguing to see how our leaders plan to address crucial issues impacting innovation, healthcare, and technology. In our industry, we thrive on pushing boundaries and discovering new solutions. It's essential to have policies that not only support progress but also prioritize safety and accessibility for all individuals. Regardless of the election outcome, I remain optimistic that there will be a continued emphasis on advancing science and technology for the greater good. Excited to see how one of these candidates will shape our future. #PresidentialDebate #TechInBiopharma #Innovation #HealthcarePolicy

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗵𝗼𝗹𝗱 𝗳𝗼𝗿 𝗖𝗮𝘁𝗮𝗹𝗲𝗻𝘁 𝗮𝗻𝗱 𝗶𝘀 𝗶𝘁 𝘁𝗵𝗲 𝗽𝗲𝗿𝗳𝗲𝗰𝘁 𝘀𝘁𝗼𝗿𝗺 𝗳𝗼𝗿 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗘𝗾𝘂𝗶𝘁𝘆? With the events that have unfolded at Catalent resulting in a number of leaders transitioning away from the business - does it now make the organisation the perfect storm for PE carve out and acquisition? Catalent has proliferated over the years through acquisition and leaned on some thick and fast hiring strategies at all levels of the organisation, to keep up with the demands of the market through the pandemic years. However, a combination of a drop-off in the COVID market, mixed in with macro-economic pressures has meant that the Top 5 CDMO player has had to rethink its approach for 2023 and beyond. With Catalent having so many separate business units and sites globally, there is a chance that we could start to see some carve-outs taking place as we move into 2024. Let me know if you agree or have any differing thoughts in the comments... #PrivateEquity #Healthcare #CDMO #Catalent #FraserDoveInternational

Adapting to challenges can lead to unprecedented successes. Dive into the transformative journey of Pfizer and its unexpected breakthrough with Viagra. A testament to the power of flexibility in business and innovation. Let's be inspired to pivot when needed. #SuccessThroughAdaptability #PersonalGrowthInBusiness #ViagraInnovation #PfizerLeadership

We are GenomeKey, a team of scientists, engineers, clinicians, commercial diagnostic professionals and entrepreneurs who want to create a new standard of diagnostics using the latest science and technology. Learn more about our work at genomekey.com #nextgenerationsequencing #precisionmedicine #amr #wgs #genomekey #sepsisdiagnostics

Breaking into the market with your first drug? Our latest blog dives into the journey from R&D to launch day. Discover how to set your vision, build a patient-centric culture, and attract top talent. Plus, learn how Compass’s expert consultants can keep your launch on schedule. Ready to turn groundbreaking research into real-world impact? Read the blog here: https://lnkd.in/es3HTW8Y #FirstTimeLauncher #DrugLaunchSuccess #DrugLaunchTips #LifeSciencesTrends